The Cambridge Bioethics Education Working Groups: Connecting Bioethics Educators Around the World

The purpose of the Cambridge Bioethics Education Working Groups is to encourage people and institutions to work together on developing bioethics education in their countries. These focus groups invite others to share their information and develop mutual projects to further how bioethics is taught in universities, hospitals, and for the general public.

https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/cambridge-bioethics-education-working-groups

CLINICAL NEUROETHICS ADVISORY BOARD

EDITOR
Thomasine Kushner, University of California, Berkeley
kushnertk@gmail.com

ASSOCIATE EDITOR
James Giordano, Georgetown University Medical Center

EDITORIAL BOARD
Yves Agid, Institut du Cerveau et de la Moelle Épinière, France
Jennifer Chandler, University of Ottawa, Canada
Markus Christen, University of Zurich, Switzerland
Joseph J. Fins, Weill Medical College of Cornell University, New York
Paul J. Ford, Department of Bioethics, Cleveland Clinic
Grant Gillett, University of Otago Medical School, New Zealand
John Harris, University of Manchester, England
Stephen Hauser, University of California, San Francisco
Judy Illes, The University of British Columbia, Canada
Philipp Kellmeyer, University of Freiburg Medical Center, Germany
Catherine Madison, California Pacific Medical Center, San Francisco
Christine Mitchell, Harvard Medical School
Erik Parens, The Hastings Center, Garrison, New York
John R. Shook, University at Buffalo
Alan Yee, California Pacific Medical Center

Neuroethics Network/Cambridge Consortium for Bioethics Education/International Bioethics Retreat
http://www.icmbioethics.com/cambridge-home.html
Cambridge Quarterly of Healthcare Ethics
Volume 28, Number 1, January 2019
CONTENTS

Contributors 1

Special Section: Genome Editing: Biomedical and Ethical Perspectives

Guest Editors: VOJIN RAKIĆ AND ARTHUR CAPLAN

Introduction: The Ethical Frontiers of Gene Editing
ARTHUR CAPLAN AND VOJIN RAKIĆ 4

Why We Should Defend Gene Editing as Eugenics
NICHOLAS AGAR 9

Commentary: From Liberal Eugenics to Political Biology
NATHAN EMMERICH AND BERT GORDIJN 20

Gene Doping—in Animals? Ethical Issues at the Intersection of Animal Use, Gene Editing, and Sports Ethics
CAROLYN P. NEUHAUS AND BRENDAN PARENT 26

Commentary: Setting the Bar Higher
NICOLAS DELON 40

Genome Editing for Involuntary Moral Enhancement
VOJIN RAKIĆ 46

Commentary: The Implementation Ethics of Moral Enhancement
NICHOLAS AGAR 55

Can the Thought of Teilhard de Chardin Carry Us Past Current Contentious Discussions of Gene Editing Technologies?
MÁRIA ŠULEKOVÁ AND KEVIN T. FITZGERALD 62

Regulating Genome Editing: For an Enlightened Democratic Governance
GIULIA CAVALIERE, KATRIEN DEVOLDER, AND ALBERTO GIUBILINI 76

Commentary: Enlightened Democracy in Practice
OLIVER FEENEY 89

Gene Drives and Genome Modification in Nonhuman Animals: A Concern for Informed Consent?
JOANNA SMOLENSKI 93

Let Us Assume That Gene Editing Is Safe—The Role of Safety Arguments in the Gene Editing Debate
SØREN HOLM 100

Contents continued
Contents continued

A Defense of Limited Regulation of Human Genetic Therapies
James J. Hughes 112

Symposium on Ethics Dumping

Editorial: Looking for Justice from the Health Industry
Doris Schroeder and Julie Cook 121

Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An Industry Approach
Ariella Kelman, Anna Kang, and Brian Crawford 124

Healthy Volunteers for Clinical Trials in Resource-Poor Settings: National Registries Can Address Ethical and Safety Concerns
Francois Bombart 134

Involving Patients in Research? Responsible Research and Innovation in Small- and Medium-Sized European Health care Enterprises
Kalypso Iordanou 144

Working Together to Make the World a Healthier Place: Desiderata for the Pharmaceutical Industry
Klaus M. Leisinger and Kate Chatfield 153

Departments and Columns

Responses and Dialogue
John Harris: An Appreciation
John J. Paris, SJ 165

Research Ethics
“Go Ask Alice”: The Case for Researching Schedule I Drugs
Kenneth V. Iserson 168

Bioethics and Information Technology
Christoph U. Lehmann, Carolyn Petersen, Haresh Bhatia, Eta S. Berner, and Kenneth W. Goodman 178

CQ Review
The Future of Bioethics; International Dialogues
Edited by Akira Akabayashi
Reviewed by Shuma Yoshida and Shintaro Tamate 186